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Introduction 
 
As part of the project „Horizon Scanning in Oncology“ (further information can be found here: 
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie), 9 information sources are scanned 
frequently to identify emerging anticancer drugs. 
Every 3 months, these anticancer therapies are filtered (i.e. in most cases defined as availability of 
phase III results; for orphan drugs also phase II) to identify drugs at/around the same time as the 
accompanying drug licensing decisions of the EMA.  
An expert panel consisting of oncologists and pharmacists then applies 5 prioritisation criteria to 
elicit those anti-cancer therapies which might be associated with either a considerable impact on 
financial resources or a substantial health benefit.  
For the 20
th
 prioritisation (September 2014), 7 were filtered out of 145 identified drugs and were 
sent to prioritisation. Of these, 4 drugs were ranked as ‘highly relevant’ by the expert panel, 3 as 
‘relevant’ and none as ‘not relevant’. For ‘highly relevant’ drugs, further information including, for 
example, abstracts of phase III studies and licensing status is contained in this document. 
The summary judgements of the expert panel for all drugs are provided in the following table. 
 
No Filtered Drugs - 20
th
 prioritisation 3
rd
 quarter 2014 Overall category 
1.  Ramucirumab (Cyramza
®
) for the second-line therapy of stage IV NSCLC Relevant 
2.  Exemestane (Aromasin
®
) for premenopausal women with endocrine 
responsive breast cance 
Relevant 
3.  Idelalisib (GS-1101) for relapsed chronic lymphocytic leukaemia Highly relevant 
4.  Lenalidomide (Revlimid™) induction/maintenance therapy in patients with 
newly diagnosed multiple myeloma 
Highly relevant 
5.  Lenalidomide (Revlimid™) for first line therapy in transplant-ineligible 
patients with multiple myeloma 
Highly relevant 
6.  Trebananib (AMG 386) for recurrent epithelial ovarian, primary peritoneal 
or fallopian tube cancers 
Relevant 
7.  Enzalutamide, MDV3100 (Xtandi
®
) in chemotherapy-naive patients with 
castration resistant prostate cancer 
Highly relevant 
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1 Chronic lymphocytic leukaemia 
Idelalisib (GS-1101) for relapsed chronic lymphocytic leukaemia 
 
Drug description: an oral inhibitor of the delta isoform of phosphatidylinositol 3-kinase 
Incidence in Austria: ~ 350 CLL patients newly diagnosed/year 
EMA/FDA licensing for this indication: positive decision by European Medicines 
Agency's Committee for Medicinal Products for Human Use in July 2014 /- 
Phase III results: 
 
Furman et al. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. NEJM 
(2014); 1–11. 
 
Background 
Patients with relapsed chronic lymphocytic leukemia (CLL) who have clinically significant coexisting 
medical conditions are less able to undergo standard chemotherapy. Effective therapies with 
acceptable side-effect profiles are needed for this patient population. 
 
Methods 
In this multicenter, randomized, double-blind, placebo-controlled, phase 3 study, we assessed the 
efficacy and safety of idelalisib, an oral inhibitor of the delta isoform of phosphatidylinositol 3-kinase, in 
combination with rituximab versus rituximab plus placebo. We randomly assigned 220 patients with 
decreased renal function, previous therapy-induced myelosuppression, or major coexisting illnesses to 
receive rituximab and either idelalisib (at a dose of 150 mg) or placebo twice daily. The primary end 
point was progression-free survival. At the first prespecified interim analysis, the study was stopped 
early on the recommendation of the data and safety monitoring board owing to overwhelming efficacy. 
 
Results 
The median progression-free survival was 5.5 months in the placebo group and was not reached in 
the idelalisib group (hazard ratio for progression or death in the idelalisib group, 0.15; P<0.001). 
Patients receiving idelalisib versus those receiving placebo had improved rates of overall response 
(81% vs. 13%; odds ratio, 29.92; P<0.001) and overall survival at 12 months (92% vs. 80%; hazard 
ratio for death, 0.28; P = 0.02). Serious adverse events occurred in 40% of the patients receiving 
idelalisib and rituximab and in 35% of those receiving placebo and rituximab. 
 
Conclusion 
The combination of idelalisib and rituximab, as compared with placebo and rituximab, significantly 
improved progression-free survival, response rate, and overall survival among patients with relapsed 
CLL who were less able to undergo chemotherapy. 
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2 Multiple Myeloma 
Lenalidomide (Revlimid™) induction/maintenance therapy in 
patients with newly diagnosed multiple myeloma  
 
Drug description: an orally administered thalidomide analogue 
Incidence in Austria: ~ 600  patients newly diagnosed/year 
EMA/FDA licensing for this indication: -/- 
Phase III results: 
Palumbo et al. Autologous Transplantation and Maintenance Therapy in Multiple Myeloma. 
NEJM (2014); 371: 895-905. 
 
Background 
This open-label, randomized, phase 3 study compared melphalan at a dose of 200 mg per square 
meter of body-surface area plus autologous stem-cell transplantation with melphalan–prednisone–
lenalidomide (MPR) and compared lenalidomide maintenance therapy with no maintenance therapy in 
patients with newly diagnosed multiple myeloma. 
 
Methods 
We randomly assigned 273 patients 65 years of age or younger to high-dose melphalan plus stem-cell 
transplantation or MPR consolidation therapy after induction, and 251 patients to lenalidomide 
maintenance therapy or no maintenance therapy. The primary end point was progression-free survival. 
 
Results 
The median follow-up period was 51.2 months. Both progression-free and overall survival were 
significantly longer with high-dose melphalan plus stem-cell transplantation than with MPR (median 
progression-free survival, 43.0 months vs. 22.4 months; hazard ratio for progression or death, 0.44; 
95% confidence interval [CI], 0.32 to 0.61; P<0.001; and 4-year overall survival, 81.6% vs. 65.3%; 
hazard ratio for death, 0.55; 95% CI, 0.32 to 0.93; P=0.02). Median progression-free survival was 
significantly longer with lenalidomide maintenance than with no maintenance (41.9 months vs. 21.6 
months; hazard ratio for progression or death, 0.47; 95% CI, 0.33 to 0.65; P<0.001), but 3-year overall 
survival was not significantly prolonged (88.0% vs. 79.2%; hazard ratio for death, 0.64; 95% CI, 0.36 
to 1.15; P=0.14). Grade 3 or 4 neutropenia was significantly more frequent with high-dose melphalan 
than with MPR (94.3% vs. 51.5%), as were gastrointestinal adverse events (18.4% vs. 0%) and 
infections (16.3% vs. 0.8%); neutropenia and dermatologic toxic effects were more frequent with 
lenalidomide maintenance than with no maintenance (23.3% vs. 0% and 4.3% vs. 0%, respectively). 
 
Conclusions 
Consolidation therapy with high-dose melphalan plus stem-cell transplantation, as compared with 
MPR, significantly prolonged progression-free and overall survival among patients with multiple 
myeloma who were 65 years of age or younger. Lenalidomide maintenance, as compared with no 
maintenance, significantly prolonged progression-free survival. 
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Lenalidomide (Revlimid™) for first line therapy in transplant-
ineligible patients with multiple myeloma 
 
Drug description: an orally administered thalidomide analogue 
Incidence in Austria: ~ 600 patients newly diagnosed/year 
EMA/FDA licensing for this indication: -/- 
Phase III results: 
Benboubker et al. Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with 
Myeloma. NEJM (2014); 371: 906-917. 
 
Background 
The combination melphalan–prednisone–thalidomide (MPT) is considered a standard therapy for 
patients with myeloma who are ineligible for stem-cell transplantation. However, emerging data on the 
use of lenalidomide and low-dose dexamethasone warrant a prospective comparison of the two 
approaches. 
Methods 
We randomly assigned 1623 patients to lenalidomide and dexamethasone in 28-day cycles until 
disease progression (535 patients), to the same combination for 72 weeks (18 cycles; 541 patients), or 
to MPT for 72 weeks (547 patients). The primary end point was progression-free survival with 
continuous lenalidomide–dexamethasone versus MPT. 
Results 
The median progression-free survival was 25.5 months with continuous lenalidomide–dexamethasone, 
20.7 months with 18 cycles of lenalidomide–dexamethasone, and 21.2 months with MPT (hazard ratio 
for the risk of progression or death, 0.72 for continuous lenalidomide–dexamethasone vs. MPT and 
0.70 for continuous lenalidomide–dexamethasone vs. 18 cycles of lenalidomide–dexamethasone; 
P<0.001 for both comparisons). Continuous lenalidomide–dexamethasone was superior to MPT for all 
secondary efficacy end points, including overall survival (at the interim analysis). Overall survival at 4 
years was 59% with continuous lenalidomide–dexamethasone, 56% with 18 cycles of lenalidomide–
dexamethasone, and 51% with MPT. Grade 3 or 4 adverse events were somewhat less frequent with 
continuous lenalidomide–dexamethasone than with MPT (70% vs. 78%). As compared with MPT, 
continuous lenalidomide–dexamethasone was associated with fewer hematologic and neurologic toxic 
events, a moderate increase in infections, and fewer second primary hematologic cancers. 
 
Interpretation 
IAs compared with MPT, continuous lenalidomide–dexamethasone given until disease progression 
was associated with a significant improvement in progression-free survival, with an overall survival 
benefit at the interim analysis, among patients with newly diagnosed multiple myeloma who were 
ineligible for stem-cell transplantation. 
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3 Prostate Cancer 
Enzalutamide, MDV3100 (Xtandi®) in chemotherapy-naive patients 
with castration resistant prostate cancer  
 
Drug description: first oral androgen receptor signalling inhibitor (ARSI) 
Incidence in Austria: 4,800 men/year newly diagnosed with prostate cancer 
EMA/FDA licensing for this indication: -/- 
Phase III results: 
 
Beer et al. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy NEJM (2014); 371: 
424-433. 
 
Background 
Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic 
castration-resistant prostate cancer in whom the disease has progressed after chemotherapy. New 
treatment options are needed for patients with metastatic prostate cancer who have not received 
chemotherapy, in whom the disease has progressed despite androgen-deprivation therapy 
 
Methods 
In this double-blind, phase 3 study, we randomly assigned 1717 patients to receive either 
enzalutamide (at a dose of 160 mg) or placebo once daily. The coprimary end points were 
radiographic progression-free survival and overall survival. 
 
Results 
The study was stopped after a planned interim analysis, conducted when 540 deaths had been 
reported, showed a benefit of the active treatment. The rate of radiographic progression-free survival 
at 12 months was 65% among patients treated with enzalutamide, as compared with 14% among 
patients receiving placebo (81% risk reduction; hazard ratio in the enzalutamide group, 0.19; 95% 
confidence interval [CI], 0.15 to 0.23; P<0.001). A total of 626 patients (72%) in the enzalutamide 
group, as compared with 532 patients (63%) in the placebo group, were alive at the data-cutoff date 
(29% reduction in the risk of death; hazard ratio, 0.71; 95% CI, 0.60 to 0.84; P<0.001). The benefit of 
enzalutamide was shown with respect to all secondary end points, including the time until the initiation 
of cytotoxic chemotherapy (hazard ratio, 0.35), the time until the first skeletal-related event (hazard 
ratio, 0.72), a complete or partial soft-tissue response (59% vs. 5%), the time until prostate-specific 
antigen (PSA) progression (hazard ratio, 0.17), and a rate of decline of at least 50% in PSA (78% vs. 
3%) (P<0.001 for all comparisons). Fatigue and hypertension were the most common clinically 
relevant adverse events associated with enzalutamide treatment. 
 
Conclusion 
Enzalutamide significantly decreased the risk of radiographic progression and death and delayed the 
initiation of chemotherapy in men with metastatic prostate cancer. 
